Why Is Hims Stock Falling After Q1 Earnings: What Indian Investors Must Know

Hims & Hers Health (NYSE: HIMS) reported its Q1 2026 earnings on May 11, and the market did not like what it saw. Shares slid roughly 10-11.5% in after-hours trading, reversing gains the stock had built over recent weeks. For Indian investors who have been drawn to this high-growth US healthcare play, the selloff raises a critical question: is this a structural crack or a temporary stumble during a strategic pivot?

The answer, as the numbers reveal, is more nuanced than the headlines suggest. Let’s break it down.

What Does Hims & Hers Actually Do?

Think of Hims & Hers as a more advanced, consumer-focused version of Pharmeasy in the US. The company runs a telehealth platform where users can consult licensed doctors online and get prescription medicines delivered directly to their homes. It focuses on areas like hair loss, skincare, mental health, erectile dysfunction and now weight loss.

The business model is simple and subscription-driven. Users pay a recurring monthly fee, complete an online consultation, and receive medicines at prices that are often lower than traditional pharmacies.

The company became a major market story in 2024 when blockbuster weight-loss drugs like Ozempic and Wegovy faced supply shortages in the US. Hims started offering compounded versions of the same active ingredient at much cheaper prices, which drove massive customer demand and helped revenue surge 111% in Q1 2025.

But what the FDA giveth, the FDA can taketh away.

What the Hims Earnings Report Actually Said

The headline numbers were bad. But the story inside the earnings report is more revealing.

Source: HIMS Earnings Release

Revenue: $608.1 million, up 4% year over year, but $8.7 million below the analyst consensus of $616.8 million. In context, this company grew revenue by 111% in the same quarter last year. A deceleration to 4% is jarring.

Net Loss: The company swung to a net loss of $92.1 million (or $0.40 per share), compared to a profit of $49.5 million ($0.20 per share) in Q1 2025. Wall Street had expected a marginal profit of $0.03 per share. The swing in EPS from +$0.20 to -$0.40 in one year represents a complete reversal of profitability.

Gross Margin: This is the number that deserves far more attention than it is getting. Gross margin collapsed from 73% a year ago to 65% this quarter. For a software-like subscription health business, losing 8 percentage points of gross margin in one year signals a fundamental shift in cost structure, not just a one-time blip.

Adjusted EBITDA Margin: Fell from 16% to 7.3%. This is the operational profitability measure most investors track for growth companies, and halving it in a year is not a small thing.

US Revenue: Fell 8% year over year to $529.9 million. The company that built its brand in America is now shrinking in its home market.

The Hidden Number: Why the Margin Collapse Is the Real Story

The $92 million net loss contains several one-time charges: $33.5 million in restructuring costs tied to inventory write-downs, $15 million in legal settlement costs, and $36.9 million in stock-based compensation. Stripping these out makes the loss look more manageable.

But the gross margin decline from 73% to 65% cannot be explained away by one-time charges. It reflects a structural shift: Hims is moving away from selling cheap compounded semaglutide (high margin, regulatory risk) toward selling branded Wegovy and Ozempic through its new partnerships with Novo Nordisk and Eli Lilly (lower margin, regulatory safety). Branded GLP-1 drugs carry far higher acquisition costs and lower markup potential.

In addition, monthly revenue per subscriber slipped from $85 to $80. Subscribers are growing (up 9% year over year to 2.6 million), but each subscriber is generating less revenue. That is a combination that compresses economics even as the top line grows.

The restructuring charge of $33.5 million itself tells a story: the company had to write down semaglutide inventory it can no longer sell the way it planned to. That is not just a cost item. It represents the physical consequence of a business model that existed because of an FDA shortage window now closing.

Why Investors Were Spooked: The GLP-1 Pivot Risk

Hims built a rocket ship on compounded semaglutide. When the FDA declared the Ozempic and Wegovy shortage over in early 2025, that rocket ship lost its fuel. The company has since settled its legal dispute with Novo Nordisk and struck a deal to distribute branded GLP-1 drugs instead.

The problem is the economics of that transition. Compounded semaglutide cost Hims very little to source and could be marked up significantly. Branded Wegovy and Ozempic are priced by Novo Nordisk. Hims is now a distributor in that arrangement, not a manufacturer. The margin profile changes dramatically.

Investors are also watching the FDA's proposal to remove semaglutide, tirzepatide, and liraglutide from the 503B bulk compounding list. If finalized, this regulatory move would validate Hims' pivot away from compounding, but it also formally ends the window that allowed this business to scale so quickly.

The honest concern is this: can Hims sustain 2.6 million subscribers and grow ARPU (average revenue per user) when the low-cost product that attracted many of those subscribers is going away?

Are Investor Concerns Justified? Here Is the Other Side of the Data

The selloff is understandable, but the bull case is not dead. Three numbers stand out.

• First, Q2 2026 guidance of $680 to $700 million beats the analyst consensus of around $659 million. That is a 6% top-line surprise in a quarter where investors feared a broader collapse. The company is guiding for 25% to 28% year-over-year revenue growth in Q2, which would represent a sharp acceleration from Q1's 4%.
• Second, international revenue grew 825% year over year in the Rest of World segment. Hims has made three acquisitions in Europe and is pending the closure of its $240 million deal for Eucalyptus, which adds Australia, Japan, Germany, and deeper UK presence. The company has guided for at least $200 million in international revenue this year, excluding Eucalyptus contributions.
• Third, operating cash flow remained healthy at $89 million in Q1. The company is generating real cash even as GAAP losses mount.

Management has reaffirmed its 2030 targets of $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA. At the current valuation, the market is essentially pricing in a significant execution risk discount on those targets.

What Should Indian Investors Investing in US Stocks Take Away?

For Indian investors accessing US markets, the Hims situation illustrates a pattern worth understanding: high-growth US healthcare companies often trade not on today's numbers, but on the narrative around tomorrow's.

When that narrative shifts, the stock moves violently, even if the underlying subscriber base and revenue remain largely intact.

A few considerations worth keeping in mind:

• The GLP-1 pivot is a known headwind, but also a forcing function. If Hims successfully transitions its weight-loss base to branded FDA-approved medications, it operates in a far less legally precarious position and has a more durable business long-term.
• Margin recovery is the key variable. If gross margins can recover toward the 70% range as the product mix stabilizes, the adjusted EBITDA profile will look very different by late 2026 or 2027.
• HIMS at its current price reflects significant uncertainty about the GLP-1 transition and margin outlook. Whether that uncertainty is sufficiently priced in, depends on how quickly the company demonstrates gross margin recovery and whether the Q2 guidance proves achievable.

The data does not scream panic, but it does demand patience and continued monitoring of margin trends over the next two quarters. The Q2 earnings report in August 2026 will be a far more decisive signal than this one.